$ROIV News
Last published 1d ago
- 1d agoROIVROIVWPriovant Announces Publication of Phase 2 BEACON Results for Brepocitinib in Cutaneous Sarcoidosis in JAMA DermatologyGlobeNewswireDURHAM, N.C., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Priovant Therapeutics today announced the publication in JAMA Dermatology of results from the Phase 2 portion of the BEACON study, a randomized, double-blind, placebo-controlled trial evaluating oral brepocitinib in adults with cutaneous sarcoidosis (CS). The publication describes improvements in skin disease activity and skin-related quality of life ...
- 2d agoROIVRoivant 2Q 2026 Earnings Call - ROIVANT SCIENCES LTDEarnings Call TranscriptsLadies and gentlemen, thank you for standing by. Welcome to the Royvent second quarter 2026 earnings call. At this time, all participants are in the listen-only mode. After the speaker's presentation, there will be a que
- 2d agoROIVRoivant Sciences Ltd. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 2d agoROIVROIVWRoivant Reports Financial Results for the Second Quarter Ended September 30, 2026, and Provides Business UpdateGlobeNewswireBASEL, Switzerland and LONDON and NEW YORK, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the second quarter ended September 30, 2026, and provided a business update.
- 2d agoROIVROIVWRoivant Reports Financial Results for the Second Quarter Ended September 30, 2026, and Provides Business UpdateGlobeNewswireLISRAYA™ (brepocitinib) generated net product revenue of $31.0 million in its first 5 weeks of launch following FDA approval in August 2026IMVT-1402 600 mg met the primary endpoint of ACR20 response at Week 28 (92.5%
- 2d agoIMVTROIVImmunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended September 30, 2026GlobeNewswireIMVT-1402 600 mg met the primary endpoint of ACR20 response at Week 28 (92.5% vs. 75.6% placebo, p=0.0139) in Period 2 (randomized withdrawal design following open-label lead-in) of the potentially registrational trial
- 1w agoROIVROIVWRoivant Social Ventures Announced Support of No Patient Left Behind with Six-Figure Organizational Legacy GiftGlobeNewswireNEW YORK, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Today Roivant Social Ventures (RSV) announced it is joining efforts with No Patient Left Behind (NPLB) to improve drug affordability and access while supporting ongoing
- 3w agoROIVBrepocitinib in NIU: CLARITY Phase 3 Study Results - ROIVANT SCIENCES LTDEarnings Call TranscriptsGood day and thank you for standing by. Welcome to the Revan's Clarity Phase 3 Study Results Conference Call. At this time, all participants are in the listen-only mode. After the speaker's presentation, there will be a
- 3w agoROIVROIVWRoivant and Priovant Announce Positive Results in CLARITY-1 and CLARITY-2 Phase 3 Trials for Brepocitinib in Non-Infectious Uveitis (NIU)GlobeNewswireBrepocitinib 45 mg once-daily achieved statistically significant benefit compared to placebo on the primary and all key secondary endpoints for each of CLARITY-1 and CLARITY-2, the two identical Phase 3 trials
- 3w agoIMVTROIVImmunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026GlobeNewswireDURHAM, N.C., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT) today announced that it will report its financial results for the second fiscal quarter ended September 30, 2026 on Monday, November 9,
- 3w agoROIVROIVWRoivant to Report Financial Results for the Second Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026GlobeNewswireBASEL, Switzerland and LONDON and NEW YORK, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Roivant (NASDAQ:ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Monday, November 9, 2026, to
- 2mo agoROIVPulmovant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier StudyGlobeNewswirePHocus met its primary endpoint, demonstrating a clinically meaningful and statistically significant placebo-adjusted reduction in pulmonary vascular resistance (PVR) of -56.3% (p<0.0001) at Week 16, the highest ever
- 2mo agoROIVROIVWRoivant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier StudyGlobeNewswirePHocus met its primary endpoint, demonstrating a clinically meaningful and statistically significant placebo-adjusted reduction in pulmonary vascular resistance (PVR) of -56.3% (p<0.0001) at Week 16, the highest ever
- 2mo agoROIVPulmovant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026GlobeNewswireWALTHAM, Mass., Sept. 06, 2026 (GLOBE NEWSWIRE) -- Pulmovant, a clinical-stage biotechnology company committed to transforming the lives of patients with pulmonary diseases, and a Roivant (NASDAQ:ROIV) company, today
- 2mo agoROIVROIVWRoivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026, and Host Investor CallGlobeNewswireBASEL, Switzerland and LONDON and NEW YORK, Sept. 06, 2026 (GLOBE NEWSWIRE) -- Roivant (NASDAQ:ROIV) and Pulmovant today announced that results from the Phase 2 PHocus study of mosliciguat in patients with pulmonary
- 2mo agoROIVLISRAYA (brepocitinib) Approval Call - ROIVANT SCIENCES LTDEarnings Call TranscriptsGood day, and thank you for standing by. Welcome to the Lizariah Approval Call. At this time, all participants are on a listen-only mode. At the speaker's presentation, there will be a question-and-answer session. To ask
- 2mo agoROIVROIVWRoivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.GlobeNewswireLISRAYA represents the first major therapeutic innovation in decades for adults with dermatomyositis (DM), a debilitating systemic autoimmune diseaseLISRAYA is a once-daily pill that directly targets key immune pathways
- 2mo agoROIVROIVWPriovant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.GlobeNewswireLISRAYA represents the first major therapeutic innovation in decades for adults with dermatomyositis (DM), a debilitating systemic autoimmune diseaseLISRAYA is a once-daily pill that directly targets key immune pathways
- 2mo agoROIVROIVWJAMA Dermatology Publishes Skin-Specific Outcomes from Phase 3 VALOR Trial Of Brepocitinib in DermatomyositisGlobeNewswireJAMA Dermatology publication includes results from VALOR skin-specific secondary endpoints, with rapid and durable improvements seen for brepocitinib 30 mg compared to placebo across multiple dimensions of cutaneous
- 3mo agoROIVROIVWRoivant Reports Financial Results for the First Quarter Ended June 30, 2026, and Provides Business UpdateGlobeNewswireCommercial preparations for brepocitinib in dermatomyositis (DM) are progressing well and on track for launch by the end of September 2026; topline data from Phase 3 study in non-infectious uveitis (NIU) expected in the
- 3mo agoIMVTROIVImmunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026GlobeNewswireAll IMVT-1402 clinical development timelines remain on track, including ongoing studies in Graves’ disease (GD), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP), difficult-to-treat
- 3mo agoROIVROIVWPriovant Announces First Patients Enrolled in Phase 3 Study (BEACON+) of Brepocitinib in Cutaneous Sarcoidosis (CS)GlobeNewswireCS is a highly morbid, chronic, and disfiguring condition with no approved therapiesBrepocitinib is the first investigational therapy to generate a positive result in a placebo-controlled CS study (Phase 2 BEACON) and
- 3mo agoROIVROIVWRoivant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026GlobeNewswireBASEL, Switzerland and LONDON and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- Roivant (NASDAQ:ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 6, 2026, to
- 3mo agoIMVTROIVImmunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026GlobeNewswireDURHAM, N.C., July 23, 2026 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT) today announced that it will report its financial results for the first quarter ended June 30, 2026 on Thursday, August 6, 2026 before
- 5mo agoROIVGoldman Sachs 47th Annual Global Healthcare ConferenceROIVANT SCIENCES LTDEarnings Call TranscriptsGreat. Thank you guys for joining us, and good morning. I guess we're still morning at the Goldman Sachs Global Healthcare Conference. I was thrilled to be joined on stage today with the Chief Executive Officer for Roy V
- 5mo agoROIVROIVWRoivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business UpdateGlobeNewswireIMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA); Immunovant will
- 6mo agoROIV2026 GLOBAL HEALTHCARE CONFERENCEROIVANT SCIENCES LTDEarnings Call TranscriptsLet's get started. Good morning, everyone. Thanks for joining the BFA Healthcare Conferences. My name is Chi Fong. I have Medina Ramadan with me today. We are both from the U.S. Biopharmaceutical Healthcare Team here at
- 6mo agoROIVROIVWRoivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provide Business Update on Wednesday, May 20, 2026GlobeNewswireBASEL, Switzerland and LONDON and NEW YORK, May 11, 2026 (GLOBE NEWSWIRE) -- Roivant (NASDAQ:ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, May 20, 2026, to
- 6mo agoIMVTROIVImmunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026GlobeNewswireDURHAM, N.C., May 11, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the fourth quarter and fiscal year ended March 31, 2026, and provide a business
- 7mo agoROIVBrepocitinib Program Expansion and Batoclimab UpdateROIVANT SCIENCES LTDEarnings Call TranscriptsGood day, and welcome to the BREPA-CIT-NIB program expansion and Butyl Climab update. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question-and-answer session.
- 7mo agoROIVROIVWRoivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)GlobeNewswireLichen planopilaris (LPP) is a highly morbid inflammatory scalp disorder that causes generally irreversible scarring hair loss, often accompanied by profound pain, itch, and burning sensations; no FDA-approved therapies
- 7mo agoROIVROIVWPriovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)GlobeNewswireLichen planopilaris (LPP) is a highly morbid inflammatory scalp disorder that causes generally irreversible scarring hair loss, often accompanied by profound pain, itch, and burning sensations; no FDA-approved therapies
- 7mo agoROIVROIVWNew England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in DermatomyositisGlobeNewswireThe results of the Phase 3 VALOR trial were published in the New England Journal of Medicine, underscoring the practice-changing potential of brepocitinib 30 mg once-daily in dermatomyositisBrepocitinib 30 mg was
- 8mo agoROIVLNP Litigation UpdateROIVANT SCIENCES LTDEarnings Call TranscriptsGood day and welcome to the LNP Litigation Update Conference Call. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a question and answer session. To ask a question
- 8mo agoABUSROIVROIVWRoivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With ModernaGlobeNewswireModerna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna's Section 1498 appealIf the $1.3 billion payment is realized, this settlement will
- 8mo agoABUSROIVGenevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With ModernaGlobeNewswireModerna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna's Section 1498 appealIf the $1.3 billion payment is realized, this settlement will
- 8mo agoROIVROIVWPriovant Announces FDA Acceptance and Priority Review of New Drug Application for Brepocitinib in DermatomyositisGlobeNewswireFDA assigns PDUFA target action date in the third quarter of calendar year 2026 with launch expected at the end of September 2026Priority Review supported by positive Phase 3 VALOR results, the first positive 52-week
- 9mo agoROIVRoivant 3Q 2025 Earnings CallROIVANT SCIENCES LTDEarnings Call TranscriptsGood day, and thank you for standing by. Welcome to the Roy Vant Third Quarter 2025 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a qu
- 9mo agoROIVROIVWPriovant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS)GlobeNewswireBrepocitinib 45 mg significantly improved cutaneous sarcoidosis disease activity, achieving a 22.3-point improvement in mean CSAMI-A at Week 16 versus a 0.7-point improvement in placebo (Δ 21.6 P<0.0001)All
- 9mo agoROIVPulmovant Announces Completion of Enrollment in the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)GlobeNewswirePHocus enrollment completed in under 12 months from first patient dosed, representing a rapid enrollment pace in pulmonary hypertension associated with interstitial lung diseaseTopline results on track for second half of
- 9mo agoROIVROIVWRoivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December 31, 2025GlobeNewswireBrepocitinib 45 mg significantly improved cutaneous sarcoidosis disease activity, achieving a 22.3-point improvement in mean CSAMI-A at Week 16 versus a 0.7-point improvement in placebo (Δ21.6 P<0.0001). Brepocitinib
- 9mo agoIMVTROIVImmunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026GlobeNewswireDURHAM, N.C. and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Immunovant (NASDAQ:IMVT) today announced that it will report its financial results for the third quarter ended December 31, 2025, and provide a business
- 9mo agoROIVROIVWRoivant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026GlobeNewswireBASEL, Switzerland and LONDON and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Roivant (NASDAQ:ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, February 6, 2026, to
- 11mo agoROIVROIVWRoivant Highlights Continued Pipeline Progress and Outlook for Company's Next Phase of Growth at 2025 Investor DayGlobeNewswireRoivant enters new phase of corporate journey with 3+ launches, 4+ NDA/BLA filings, 8+ pivotal and 3+ proof-of-concept study readouts expected over the next three yearsHighlighting clinical execution, Roivant announces
- 1y agoROIVROIVWRoivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business UpdateGlobeNewswireBASEL, Switzerland and LONDON and NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Roivant (NASDAQ:ROIV) today reported its financial results for the second quarter ended September 30, 2025, and provided a business update.
- 1y agoIMVTROIVImmunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025GlobeNewswireNEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Immunovant (NASDAQ:IMVT) today announced that it will report its financial results for the second quarter ended September 30, 2025, and provide a business update at 8:00 a.m.
- 1y agoROIVROIVWRoivant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025GlobeNewswireBASEL, Switzerland and LONDON and NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Roivant (NASDAQ:ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Monday, November 10, 2025, to
- 1y agoROIVRoivant Sciences Ltd. (ROIV) Discusses On Brepocitinib In DM: VALOR Phase 3 Study Results Conference (Transcript)Earnings Call Transcripts
- 1y agoROIVROIVWRoivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM)GlobeNewswireOnce-daily oral brepocitinib 30 mg demonstrated clinically meaningful and statistically significant improvement compared to placebo on the primary endpoint and all nine key secondary endpoints, including measurements of
- 1y agoROIVROIVWRoivant Named on Fortune Media and Great Place To Work's 2025 Best Workplaces in BioPharma ListGlobeNewswireBASEL, Switzerland and LONDON and NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Great Place To Work® and Fortune magazine have selected Roivant (NASDAQ:ROIV) for the 2025 Fortune Best Workplaces in